Corbus Pharmaceuticals Holdings (CRBP) Net Cash Flow Growth (3y) (2016 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) Net Cash Flow Growth (3y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 32.17% |
| 10 | Corbus Pharmaceuticals Holdings | 116.63 Mn | 88.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 36.09% |
| Jun 30, 2025 | 26.76% |
| Mar 31, 2025 | -62.40% |
| Dec 31, 2024 | 43.15% |
| Sep 30, 2024 | -82.77% |
| Jun 30, 2024 | 32.20% |
| Mar 31, 2024 | 26.41% |
| Dec 31, 2023 | -11.44% |
| Sep 30, 2023 | -46.95% |
| Jun 30, 2023 | -60.68% |
| Mar 31, 2023 | -38.40% |
| Dec 31, 2022 | 30.01% |
| Sep 30, 2022 | 10.04% |
| Jun 30, 2022 | -23.08% |
| Mar 31, 2022 | -12.73% |
| Dec 31, 2021 | 4.51% |
| Sep 30, 2021 | 28.37% |
| Jun 30, 2021 | -70.06% |
| Mar 31, 2021 | -62.34% |
| Dec 31, 2020 | -48.38% |